BAYER AG

Berlin-based Aignostics GmbH, a spin-out from Charité and Mayo Clinic, raised $34m in Series B funding led by Athos and HTGF, bringing total funds to $55m. The AI image analysis specialist plans to expand its digital pathology offerings for target and companion diagnostics, leveraging its RudolfV foundation model. Aignostics aims to grow in the US and collaborate with Mayo Clinic for novel data-driven models and biopharma products.

Aignostics raises $34M in Series B funding to advance AI-powered pathology and precision medicine, with plans to develop new products, expand in the US, and collaborate with Mayo Clinic on advanced foundation models.

Mass General Brigham researchers developed an AI model to identify and measure aggressive prostate cancer lesions from MRI scans, showing tumor size estimates linked to cancer recurrence or spread risk, published in Radiology.

The Business Research Company's Personalized Medicine Global Market Report 2024 forecasts the market to grow from $352.73 billion in 2023 to $590.51 billion by 2028, driven by advancements in genomics, biomarker discovery, and telemedicine. Key players include Bayer AG, Novartis AG, and Thermo Fisher Scientific Inc. The report offers insights into market size, trends, and growth opportunities.

Aignostics raises $34 million in Series B financing to support new product offerings, US expansion, and pathology foundation model development with Mayo Clinic.

AI and new technologies are crucial for early detection and personalized treatment of breast and gynecological cancers, aiming to improve accessibility and outcomes, especially in resource-limited settings.

Insilico Medicine appoints Carol Satler, M.D., PhD, as VP for Non-oncology Clinical Development, to lead validation of ISM001-055 for idiopathic pulmonary fibrosis and strategic planning for non-oncology assets. Satler, with 20+ years of experience at Pfizer, Sanofi, Bayer, Takeda/Millennium, Puretech Health, and Gilead, aims to accelerate clinical validation and bring transformative therapies to market using AI.

The global MoCoD-A treatment market, valued at USD 25 million in 2022, is projected to reach USD 89.96 million by 2033, driven by advancements in genetic and precision medicine. Key players include BridgeBio Pharma, Origin Biosciences, and Orphatech Pharmaceuticals, with treatments like BBP-871 for MoCoD-A. The market growth emphasizes the need for continued research in rare genetic diseases.

The Menopausal Hot Flashes Market report by DataM Intelligence analyzes market trends, key players (Pfizer Inc, AbbVie Inc., Bayer, etc.), and growth projections through 2024-2031. It highlights advancements in medical technologies and patient-centered care driving market growth, with regions including North America, Europe, Asia Pacific, and more covered. Key developments include Veozah's FDA approval and Elda Health's product launch.